Denmark, mentioned 8 times across podcast episodes and expert conversations analyzed by Sonic.
Driven by the success of its GLP-1 drugs, Novo Nordisk's market capitalization grew to be larger than the GDP of Denmark.
Pension funds and investors in Denmark and the United Kingdom have stated they will not participate in the SpaceX IPO due to its governance structure.
Following the success of its GLP-1 drugs, Novo Nordisk's market valuation crested at $600 billion and at one point exceeded the GDP of Denmark.